210223-01-1Relevant articles and documents
MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
-
, (2021/02/19)
This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
Synthesis and evaluation of a series of novel 2-[(4- chlorophenoxy)methyl]benzimidazoles as selective neuropeptide Y Y1 receptor antagonists
Zarrinmayeh, Hamideh,Nunes, Anne M.,Ornstein, Paul L.,Zimmerman, Dennis M.,Arnold, M. Brian,Schober, Douglas A.,Gackenheimer, Susan L.,Bruns, Robert F.,Hipskind, Philip A.,Britton, Thomas C.,Cantrell, Buddy E.,Gehlert, Donald R.
, p. 2709 - 2719 (2007/10/03)
A series of novel benzimidazoles (BI) derived from the indole 2 was synthesized and evaluated as selective neuropeptide Y (NPY) Y1 receptor antagonists with the aim of developing antiobesity drugs. In our SAR approach, the (4-chlorophenoxy)methyl group at